Veralox Therapeutics Announces EMA Orphan Drug…

Cerexa Inc. today announced it has entered into a definitive agreement to be acquired by Forest Laboratories Inc. (NYSE: FRX) for $480 million plus a potential $100 million milestone payment.

Cerexa Inc. today announced it has expanded its portfolio of novel anti-infective therapies through an in-licensing agreement with Meiji Seika Kaisha Ltd.

Cerexa, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for PPI-0903, a next-generation, broad-spectrum, cephalosporin antibiotic, for the treatment of complicated skin and skin structure infections (cSSSI) caused by methicillin-resistant Staphylococcus aureus (MRSA). Cerexa initiated a Phase 2 trial of PPI-0903 for the treatment of cSSSI in October 2005. Under the FDA Modernization Act of 1997, the Fast Track program of the FDA is designed to facilitate the development and expedite the review of a new drug that is intended for the treatment of a serious or a life-threatening condition, and demonstrates the potential to address unmet medical needs for such a condition.